U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination
    • Showing Current items.

    HHLA2 HHLA2 member of B7 family [ Homo sapiens (human) ]

    Gene ID: 11148, updated on 27-Nov-2024

    GeneRIFs: Gene References Into Functions

    GeneRIFPubMed TitleDate
    HHLA2 promotes hepatoma cell proliferation, migration, and invasion via SPP1/PI3K/AKT signaling pathway.

    HHLA2 promotes hepatoma cell proliferation, migration, and invasion via SPP1/PI3K/AKT signaling pathway.
    Wang J, Yang K, Yang X, Jin T, Tian Y, Dai C, Xu F.

    07/11/2024
    HHLA2 deficiency inhibits pancreatic cancer progression and THP-1 macrophage M2 polarization via EGFR/MAPK/ERK and mTOR/AKT pathway.

    HHLA2 deficiency inhibits pancreatic cancer progression and THP-1 macrophage M2 polarization via EGFR/MAPK/ERK and mTOR/AKT pathway.
    Zhou S, Wang Z, Zhao D, Fu Y, Zhang S, Wang Z, Zou X., Free PMC Article

    05/24/2024
    HHLA2 is more significantly associated with poor prognosis in TSCC than PD-L1.

    HHLA2 is more significantly associated with poor prognosis in TSCC than PD-L1.
    Li Y, Yang Q, Yang X, Ge J, Xu T, Liu H.

    02/27/2024
    Regulation of HHLA2 expression in kidney cancer and myeloid cells.

    Regulation of HHLA2 expression in kidney cancer and myeloid cells.
    Shigemura T, Perrot N, Huang Z, Bhatt RS, Sheshdeh AB, Ahmar NE, Ghandour F, Signoretti S, McDermott DF, Freeman GJ, Mahoney KM., Free PMC Article

    11/1/2023
    HHLA2 immune-regulatory roles in cancer.

    HHLA2 immune-regulatory roles in cancer.
    Mortezaee K.

    07/19/2023
    KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy.

    KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy.
    Li Y, Lv C, Yu Y, Wu B, Zhang Y, Lang Q, Liang Z, Zhong C, Shi Y, Han S, Xu F, Tian Y., Free PMC Article

    05/4/2023
    Overexpression and Role of HHLA2, a Novel Immune Checkpoint, in Colorectal Cancer.

    Overexpression and Role of HHLA2, a Novel Immune Checkpoint, in Colorectal Cancer.
    Kula A, Dawidowicz M, Mielcarska S, Kiczmer P, Skiba H, Krygier M, Chrabańska M, Piecuch J, Szrot M, Robotycka J, Ochman B, Strzałkowska B, Czuba Z, Świętochowska E, Waniczek D., Free PMC Article

    03/31/2023
    Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma.

    Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma.
    Nishihara D, Kijima T, Arai K, Kamai T., Free PMC Article

    03/24/2023
    Decrease of Membrane B7-H5 on CD14+ Cells in Severe Acute Pancreatitis Is Related to RANSON Scores and APACHE II Scores.

    Decrease of Membrane B7-H5 on CD14+ Cells in Severe Acute Pancreatitis Is Related to RANSON Scores and APACHE II Scores.
    Xu R, Xie S, Gong J, Chen W, Jin Y, Huang J.

    03/16/2023
    Immunosuppression by Inflammation-Stimulated Amplification of Myeloid-Derived Suppressor Cells and Changes in Expression of Immune Checkpoint HHLA2 in Chronic Obstructive Pulmonary Disease.

    Immunosuppression by Inflammation-Stimulated Amplification of Myeloid-Derived Suppressor Cells and Changes in Expression of Immune Checkpoint HHLA2 in Chronic Obstructive Pulmonary Disease.
    Xu L, Li F, Jiang M, Li Z, Xu D, Jing J, Wang J, Ding J., Free PMC Article

    03/2/2023
    Silencing tumor-intrinsic HHLA2 potentiates the anti-tumoral effect of paclitaxel on MG63 cells: Another side of immune checkpoint.

    Silencing tumor-intrinsic HHLA2 potentiates the anti-tumoral effect of paclitaxel on MG63 cells: Another side of immune checkpoint.
    Ahangar NK, Khalaj-Kondori M, Alizadeh N, Mokhtarzadeh A, Baghbanzadeh A, Shadbad MA, Dolatkhah K, Baradaran B.

    02/4/2023
    HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.

    HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
    Huang FX, Wu JW, Cheng XQ, Wang JH, Wen XZ, Li JJ, Zhang Q, Jiang H, Ding QY, Zhu XF, Zhang XS, Ding Y, Li DD., Free PMC Article

    09/3/2022
    HHLA2 promotes tumor progression by long noncoding RNA H19 in human gallbladder cancer.

    HHLA2 promotes tumor progression by long non‑coding RNA H19 in human gallbladder cancer.
    Zhang Y, Li H, Lv C, Wu B, Yu Y, Zhong C, Lang Q, Liang Z, Li Y, Shi Y, Zhang J, Xu F, Tian Y., Free PMC Article

    08/20/2022
    The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma.

    The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma.
    Zhu D, Liu Y, Chen J, Wang Q, Li Y, Zhu Y, Feng J, Jiang J., Free PMC Article

    07/23/2022
    High expression of HHLA2 predicts poor prognosis in medullary thyroid carcinoma.

    High expression of HHLA2 predicts poor prognosis in medullary thyroid carcinoma.
    Niu Y, Wang W, Jiang X, Huang Y, Yan S, Jiang Y.

    07/16/2022
    HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma.

    HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma.
    Liao X, Zhang D.

    07/9/2022
    HHLA2 Activates the JAK/STAT Signaling Pathway by Binding to TMIGD2 in Hepatocellular Carcinoma Cells.

    HHLA2 Activates the JAK/STAT Signaling Pathway by Binding to TMIGD2 in Hepatocellular Carcinoma Cells.
    Guo H, Zhang C, Tang X, Zhang T, Liu Y, Yu H, Li Y, Wang R.

    06/18/2022
    Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy.

    Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy.
    Ying H, Xu J, Zhang X, Liang T, Bai X., Free PMC Article

    05/21/2022
    Different clinical significance of novel B7 family checkpoints VISTA and HHLA2 in human lung adenocarcinoma.

    Different clinical significance of novel B7 family checkpoints VISTA and HHLA2 in human lung adenocarcinoma.
    Long L, Zhang L, Yang Y, Zhou Y, Chen H.

    05/7/2022
    Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma.

    Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma.
    Ding L, Yu Q, Yang S, Yang WJ, Liu T, Xian JR, Tian TT, Li T, Chen W, Wang BL, Pan BS, Zhou J, Fan J, Yang XR, Guo W., Free PMC Article

    04/16/2022
    Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells.

    Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells.
    Wang R, Guo H, Tang X, Zhang T, Liu Y, Zhang C, Yu H, Li Y.

    03/26/2022
    KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target.

    KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target.
    Wei Y, Ren X, Galbo PM Jr, Moerdler S, Wang H, Sica RA, Etemad-Gilbertson B, Shi L, Zhu L, Tang X, Lin Q, Peng M, Guan F, Zheng D, Chinai JM, Zang X., Free PMC Article

    03/12/2022
    Coexpression of HHLA2 and PD-L1 on Tumor Cells Independently Predicts the Survival of Spinal Chordoma Patients.

    Coexpression of HHLA2 and PD-L1 on Tumor Cells Independently Predicts the Survival of Spinal Chordoma Patients.
    Xia C, Huang W, Chen YL, Fu HB, Tang M, Zhang TL, Li J, Lv GH, Yan YG, Ouyang ZH, Yao N, Wang C, Zou MX., Free PMC Article

    03/5/2022
    HHLA2 deficiency inhibits non-small cell lung cancer progression and THP-1 macrophage M2 polarization.

    HHLA2 deficiency inhibits non-small cell lung cancer progression and THP-1 macrophage M2 polarization.
    Sun W, Li S, Tang G, Sun S, Luo Y, Bai R, Han L, Jiang X, Gao Y, Huang Z, Zhang J, Gong Y, Xie C., Free PMC Article

    02/19/2022
    B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling.

    B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling.
    Rieder SA, Wang J, White N, Qadri A, Menard C, Stephens G, Karnell JL, Rudd CE, Kolbeck R., Free PMC Article

    01/29/2022
    firstprevious page of 2 nextlast